Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

ziv-aflibercept

View Patient Information
A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:aflibercept
AVE0005
vascular endothelial growth factor trap
VEGF Trap
VEGF Trap R1R2
US brand name:Eylea
Zaltrap
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search